We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

Myeloma Patient Registered to Run His 90th Marathon with Cancer
Don Wright didn’t let his 2003 myeloma diagnosis stop him in tracks. This weekend, Don is registered to run his 90th marathon with myeloma in Washington, D.C. The 74-year old says he’s managed his cancer for seven of the last twelve years with oral cancer therapies, but knows “multiple myeloma cannot be cured, so I am counting on continuing progress, research and access to the latest treatments to provide the next remission and the remission after that.”

Of Mice and Men and Elephants: Does Size Determine Our Cancer Risk?
In his blog this week, IMF Chairman Dr. Brian Durie discusses a recent story in the New York Times about the paradox of mammal size and cancer risk. Oncologists at the University of Utah’s Huntsman Cancer Institute and evolutionary biologists at the University of Chicago have published a study that examines the uncanny ability of our largest mammals, elephants, to fight cancer.

IMF's 9th Annual Comedy Gala Raises $600,000 for Myeloma Research
The IMF’s 9th Annual Comedy Celebration was a great success again this year, raising $600,000 for the Peter Boyle Research Fund and the IMF’s Black Swan Research Initiative. "Anyone who was lucky enough to be at the Wilshire Ebell Theatre on Saturday night will tell you Peter Boyle's memory —and legacy of laughter – is alive and well," writes LA Times reporter Adam Tschorn in his coverage of the evening. View a photo gallery of the event and read the full story, HERE.

In the News: Myeloma Debates, Drug Costs, Reading that Matters
IMF Chairman Dr. Brian Durie recaps the International Myeloma Workshop (IMW) meeting in Rome, where myeloma experts debated, among other questions, whether we are curing myeloma. He also comments on recent news articles investigating the rise of drug prices, the value of calcium supplements, and if tea is as good for you as coffee. And finally, he connects the dots between antimatter and PET scans.

Click here to view the replay of Living Well with Myeloma: NLB Members Answers Key Patient and Caregiver Questions teleconference

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Cleveland Clinic Taussig Cancer Institute
Multiple Myeloma Program
Cleveland, Ohio

Teresa Miceli, RN, BSN, OCN
Mayo Clinic-Rochester
Rochester, Minnesota


ARROW clinical trial fact sheet
A Randomized, Open-label, Phase III Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib (Kyprolis®) in Combination with Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

Black Swan Research Initiative Team Member Wins Prestigious Award
Dr. Bruno Paiva, a member of IMF's Black Swan Research Initiative team, won the Bart Barlogie Young Investigator Award on Saturday at the International Myeloma Workshop in Rome. Dr. Paiva's primary research area is the assessment of minimal residual disease (MRD), and in his blog this week, IMF Chairman Dr. Brian Durie writes, "This award acknowledges Bruno individually and the importance of the MRD approach to searching for a cure for myeloma."

Janssen’s daratumumab accepted for accelerated CHMP assessment for treatment of European patients with heavily pre-treated multiple myeloma
Janssen-Cilag International NV announced on September 25, 2015 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has accepted its request for an accelerated assessment of the daratumumab Marketing Authorisation Application (MAA). This acceptance follows the earlier regulatory submission of a MAA which seeks authorisation of daratumumab as a single agent for the treatment of patients with relapsed and refractory multiple myeloma and is currently pending validation by the EMA.

New Study Investigates Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
The results of the first clinical trial to investigate carfilzomib (Kyprolis®), pomalidomide (Pomalyst®), and dexamethasone (CPD) in multiple myeloma were published last week in the journal BLOOD . IMF Chairman Dr. Brian Durie, co-author of the study, calls the phase I-II results “remarkably good.” According to Dr. Durie, the well-tolerated regime produces remissions lasting approximately one year, and overall survival of close to two years, in the very-poor-risk setting of double refractory disease in which patients are resistant to both lenalidomide (Revlimid®) and bortezomib (Velcade®).

Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop
Takeda Pharmaceutical Company Limited on September 22, 2015 announced that it will highlight the ixazomib clinical development program during multiple poster sessions at the upcoming 15th International Myeloma Workshop (IMW 2015) to be held in Rome, Italy, from September 23 to 26, 2015.

previous     next      view all